Tempest Partners with Senlang to Advance In Vivo CAR-T TPST-4003 into First-in-Human Trial in China
TPST is trading near its 52-week low of $0.93 (6.3% above the low).
Summary
Tempest Therapeutics entered a collaboration with Senlang Biotechnology to develop its in vivo CAR-T candidate TPST-4003 in a first-in-human IIT in China, paying $1.5M–$2.0M in development fees while Senlang handles trial execution. First patient dosing is expected in Q4 2026, with initial safety and PD data possible in H1 2027.
Key Events · M&A and Partnerships · TPST
-
Collaboration with Senlang for TPST-4003
Tempest partnered with Heibei Senlang Biotechnology to develop TPST-4003, a CD7-targeted in vivo CAR-T, in a first-in-human IIT in China for ~10 patients with myasthenia gravis or multiple sclerosis.
-
Capital-Efficient Trial Structure
Tempest pays $1.5M–$2.0M in development fees per product, with Senlang responsible for trial execution, manufacturing, and data delivery — a structure that conserves cash for the cash-strapped company.
-
Senlang Option for China Rights
Upon delivery of the IIT data package, Senlang has a 90-day exclusive option to negotiate a definitive license for TPST-4003 in China, with economic terms to be mutually agreed.
-
Timeline to Clinical Data
First patient enrollment and dosing expected in Q4 2026; initial safety and pharmacodynamic data from the first patients could be available as early as H1 2027.
Analysis · TPST · Life Sciences
For a micro-cap biotech carrying a going-concern warning and just $1.8M in cash as of May 2026, this collaboration carves out a capital-efficient route to first-in-human data for its lead in vivo CAR-T candidate, TPST-4003. By shifting the financial burden of an initial ~10-patient IIT to China-based Senlang Biotechnology, Tempest pays only $1.5M–$2.0M in development fees — a fraction of what a U.S. trial would cost. In return, Senlang secures an exclusive option to negotiate China rights after data delivery. The deal extends the cash runway for a company that recently induced warrant exercises and sought shareholder approval for dilutive issuances just to stay afloat, and it could generate clinical proof-of-concept data by H1 2027 without immediate dilution. The market will focus on whether the IIT data can attract a larger partner or financing, but execution risk remains high given Tempest's precarious financial position.
At the time of this filing, TPST was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.2M. The 52-week trading range was $0.93 to $12.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.